VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Precision BioSciences
DTIL
$58.8M
| $149K | 0.06% |
669
+59
| +10% | +$13.1K |
|
352
Vir Biotechnology
VIR
$718M
| $149K | 0.06% |
3,568
-1,096
| -23% | -$45.8K |
|
353
CEL-SCI Corp
CVM
$79M
| $148K | 0.06% |
693
+361
| +109% | +$77.1K |
|
354
ALX Oncology
ALXO
$56.8M
| $147K | 0.06% |
6,844
+3,318
| +94% | +$71.3K |
|
355
CureVac
CVAC
$1.21B
| $146K | 0.06% |
4,258
+2,108
| +98% | +$72.3K |
|
356
Pliant Therapeutics
PLRX
$98.8M
| $146K | 0.06% |
10,827
+4,361
| +67% | +$58.8K |
|
357
Nuvation Bio
NUVB
$1.11B
| $144K | 0.05% |
16,986
-1,654
| -9% | -$14K |
|
|
HGEN
358
DELISTED
HUMANIGEN, INC.
HGEN
| $144K | 0.05% |
38,740
+28,385
| +274% | +$106K |
|
|
KLRS
359
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.8M
| $143K | 0.05% |
482
+75
| +18% | +$22.3K |
|
360
Annexon
ANNX
$226M
| $139K | 0.05% |
12,078
+3,035
| +34% | +$34.9K |
|
361
Inovio Pharmaceuticals
INO
$142M
| $139K | 0.05% |
2,316
+328
| +16% | +$19.7K |
|
362
Novavax
NVAX
$1.23B
| $139K | 0.05% |
975
-53
| -5% | -$7.56K |
|
363
Q32 Bio
QTTB
$20.1M
| $137K | 0.05% |
2,088
+489
| +31% | +$32.1K |
|
|
EVLO
364
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $135K | 0.05% |
1,113
+462
| +71% | +$56K |
|
365
Taysha Gene Therapies
TSHA
$873M
| $134K | 0.05% |
11,519
+3,251
| +39% | +$37.8K |
|
366
Edgewise Therapeutics
EWTX
$1.53B
| $131K | 0.05% |
+8,604
| New | +$131K |
|
367
ATAI Life Sciences
ATAI
$937M
| $125K | 0.05% |
+16,393
| New | +$125K |
|
|
SRNE
368
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $125K | 0.05% |
26,928
+4,463
| +20% | +$20.7K |
|
|
RUBY
369
DELISTED
Rubius Therapeutics, Inc
RUBY
| $124K | 0.05% |
12,773
+5,295
| +71% | +$51.4K |
|
370
uniQure
QURE
$929M
| $121K | 0.05% |
5,841
-246
| -4% | -$5.1K |
|
371
CytomX Therapeutics
CTMX
$338M
| $118K | 0.04% |
27,150
-2,208
| -8% | -$9.6K |
|
372
VanEck High Yield Muni ETF
HYD
$3.3B
| $104K | 0.04% |
1,669
| – | – |
|
373
Aldeyra Therapeutics
ALDX
$352M
| $97K | 0.04% |
24,298
+7,002
| +40% | +$28K |
|
|
BTX
374
BlackRock Technology and Private Equity Term Trust
BTX
$813M
| $76K | 0.03% |
5,212
-149
| -3% | -$2.17K |
|
375
BridgeBio Pharma
BBIO
$9.78B
| $72K | 0.03% |
4,304
+968
| +29% | +$16.2K |
|